WO2012137216A1 - Nouvelle formulation pharmaceutique d'alpha cétoanalogue d'acides aminés et d'acides aminés supplémentaires pour un traitement d'une maladie rénale chronique et son procédé de préparation - Google Patents

Nouvelle formulation pharmaceutique d'alpha cétoanalogue d'acides aminés et d'acides aminés supplémentaires pour un traitement d'une maladie rénale chronique et son procédé de préparation Download PDF

Info

Publication number
WO2012137216A1
WO2012137216A1 PCT/IN2011/000647 IN2011000647W WO2012137216A1 WO 2012137216 A1 WO2012137216 A1 WO 2012137216A1 IN 2011000647 W IN2011000647 W IN 2011000647W WO 2012137216 A1 WO2012137216 A1 WO 2012137216A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
pharmaceutical formulation
amino acids
alpha
polyvinyl pyrrolidone
Prior art date
Application number
PCT/IN2011/000647
Other languages
English (en)
Inventor
Saibal Chakravorty
Amit Kumar Jain
Amit Doshi
Original Assignee
Rpg Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rpg Life Sciences Limited filed Critical Rpg Life Sciences Limited
Publication of WO2012137216A1 publication Critical patent/WO2012137216A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Definitions

  • the present invention relates to a novel pharmaceutical formulation of alpha ketoanalogue of amino acids and additional amino acids for treatment of chronic kidney disease and method of its preparation.
  • the present invention relates to a novel pharmaceutical formulation comprising alpha ketoanalogue of amino acids and additional amino acids which have been surprisingly and unexpectedly found to be effective in improving controlled degradation and enhancing in-vitro dissolution of the formulation, particularly tQ overcome problem of decreased in-vitro dissolution of the tablet form of the formulation, more particularly on storage thereof.
  • the present invention relates to formulation comprising alpha ketoanalogue of amino acids and additional amino acids which have been surprisingly and unexpectedly found to be effective against moisture and heat degradation, and effective to enhance in-vitro dissolution of the formulation meaning thereby enhancing availability of the active ingredient of the formulation for efficient treatment of chronic kidney disease.
  • the present invention relates to method of preparation of formulation comprising alpha ketoanalogue of amino acids and additional amino acids having controlled degradation and enhanced in-vitro dissolution.
  • kidney failure (formerly referred as renal insufficiency or chronic renal insufficiency) describes a medical condition in which the kidneys fail to adequately filter toxins and waste products from the; blood, which may also be referred to as malfunction of kidney.
  • the problems, frequently encountered in kidney malfunction include abnormal levels of fluid, potassium, calcium, phosphate, hematuria (blood in the urine) in the body, and deranged acid levels, and in the longer term it may lead to anemia.
  • the long-term kidney problems may have significant repercussions on other diseases, such as cardiovascular disease, and a number of other diseases or health problems may cause renal failure to occur. ⁇
  • the renal failure is typically of two forms - a) acute kidney injury and b) chronic kidney disease, which may be determined by the trend in the serum creatinine level. Other factors which may help differentiate acute kidney injury from chronic kidney disease include anemia and the kidney size on ultrasound. Chronic kidney disease generally leads to anemia and small kidney size.
  • the Acute Kidney Injury also referred to as acute renal failure (ARF) is a rapidly progressive loss of renal function, generally characterized by oliguria (decreased urine production, quantified as less than 400 mL/day in adults, less than 0.5 mL/kg/h in children or less than 1 mL/kg/h in infants); body water and body fluids disturbances; and electrolyte derangement.
  • AKI can result from a variety of causes, generally classified as prerenal, intrinsic, and postrenal. An underlying cause must be identified and treated to arrest the progress, and dialysis may be necessary to bridge the time gap required for treating these fundamental causes.
  • the Chronic Kidney Disease can develop slowly. Initially it shows few symptoms.
  • the CKD can be the long-term consequence of irreversible acute disease or part of a disease progression.
  • Acute-on-Chronic Renal Failure the acute kidney injuries can be present on top of chronic kidney disease.
  • the acute part of AoCRF may be reversible, and the goal of treatment, as ⁇ vith AKI, is to return the patient to baseline renal function, typically measured by serum creatinine.
  • the AoCRF can be difficult to distinguish from chronic kidney disease if the patient has not been monitored by a physician and no baseline (i.e., past) blood work is available for comparison.
  • the renal failure is typically detected by an elevated serum creatinine level.
  • the renal failure is described as a decrease in the glomerular filtration rate (GFR).
  • All individuals with a GFR less than 60 mL/min/1.73m2 for three months are classified as having chronic kidney disease, irrespective of the presence or absence of kidney damage.
  • the rationale for including these individuals in category of chronic kidney disease is that reduction in kidney function to this level or lower represents loss of half or more of the adult level of normal kidney function, which may be associated with a number of complications.
  • the GFR may be sustained at normal or increased levels despite substantial kidney damage and that patients with kidney damage are at increased risk of the two major outcomes of chronic kidney disease, that is, loss of kidney function and development of cardiovascular disease.
  • the loss of protein in the urine is regarded as an independent marker for worsening of renal function and cardiovascular disease.
  • the British guidelines append the letter "P" to the stage of chronic kidney disease if there is significant protein loss.
  • the level of GFR is generally employed to identify the stage of renal failure.
  • GFR normal or relatively high GFR, that is GFR being equal to or more that 90 mL/min/1.73m2 indicates slightly diminished function of kidney.
  • This level of kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine test or imaging studies.
  • GFR The mild reduction in GFR, that is GFR being between 60 to 89 mL/min/1.73m2 indicates kidney damage, which is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine test or imaging studies.
  • stage 3A having GFR between 45 to 59
  • stage 3B having GFR between 30 to 44 for the purposes of screening and referral.
  • GFR severe reduction in GFR, that is, GFR being between 15 to 29 mL/min/1.73m2. This stage indicates requirement for preparation for renal replacement therapy.
  • the formulation comprising alpha ketoanalogue has been used for treatment of renal failure, and for dialysis of patients as a supplement to a protein unrestricted diet in order to compensate amino acid losses in to dialysis.
  • the additional phosphate-binding effects of ketoanalogue associated with reductions in the serum phosphate and parathyroid hormone levels have been shown in dialysis patient.
  • Ketosteril is combination of alpha ketoanalogue of amino acids and some other amino acids but such combination has been found to give very poor dissolution, and hence, results into inefficient quality for the renal treatment. Further, this known combination which is available in form of film coated tablet has been found to have poor disintegration in the aqueous medium even after taking for more than one hour, and hence, poor in-vitro dissolution. The inventors have observed that the disintegration time of the formulation known as Ketosteril is more than one hour in water as well as gastric juice at a pH of about 1.2. Further, another known combination of alfa ketoanalogue amino acids [Ketolog] has been found to have surface spotted degradation and discoloration.
  • the present invention aims to overcome above-described problems of the prior art by providing a pharmaceutical formulation comprising alpha ketoanalogue of amino acids and additional amino acids which has been, surprisingly and unexpectedly, found to have increased in-vitro dissolution and controlled degradation, particularly under moisture and heat conditions, more particularly under moisture and heat conditions during storage of its tablet form, and hence, has been, surprisingly and unexpectedly, found to be protective against moisture and heat degradation, and having enhanced in-vitro dissolution meaning thereby expected to have enhanced in-vivo bioavailability of its active ingredients for efficient treatment of chronic kidney disease.
  • the main object of the present invention is to provide a pharmaceutical formulation comprising alpha ketoanalogue of amino acids and additional amino acids, and having increased in-vitro dissolution, and reduced and controlled degradation, particularly under moisture and heat conditions, more particularly under moisture and heat conditions during storage of its tablet dosages form.
  • the another main object of the present invention is to provide a pharmaceutical formulation comprising alpha ketoanalogue of amino acids and additional amino acids, and having substantially increased in-vitro dissolution, and substantially reduced and controlled degradation, particularly under moisture and heat conditions, wherein its tablet dosages form is coated with moisture barrier coating composition.
  • the another object of the present invention is to provide a pharmaceutical formulation comprising alpha ketoanalogue of amino acids and additional amino acids, and having possibility of enhanced iri-vivo bioavailability of its active ingredients so as to achieve efficient treatment of chronic kidney disease.
  • a pharmaceutical formulation comprising alpha ketoanalogue of amino acids and additional amino acids, and having increased in-vitro dissolution, and reduced and controlled degradation, particularly under moisture and heat conditions, more particularly under moisture and heat conditions during storage of its tablet form, and having expected enhanced in-vivo bioavailability of its active ingredients so as to achieve efficient treatment of chronic kidney disease
  • the inventors have found that if croscarmellose sodium is used as disintegrant in combination with filler microcrystalline cellulose and binder polyvinyl pyrrolidone, the formulation comprising alpha ketoanalogue and additional amino acids, suprisingly and unexpectedly, demonstrates increased in-vitro dissolution, and reduced arid controlled degradation under moisture and heat conditions even during its storage in the tablet dosage form.
  • the inventors have further found that if formulation comprising alpha ketoanalogue of amino acids and additional amino acids, and croscarmellose sodium as disintegrant, microcrystalline cellulose as filler and polyvinyl pyrrolidone as binder is coated with moisture barrier coating composition comprising polyvinyl alcohol as film former, soya lecithin as plasticizer and solubilizing agent and xanthan gum as stabilizer and suspension agent, the in-vitro dissolution is, suprisingly and unexpectedly substantially increased, and degradation is, suprisingly and unexpectedly substantially reduced and controlled under the moisture and heat conditions even during its accelerated stability storage conditions as per ICH (International Conference on Harmonization) in the tablet dosage form.
  • moisture barrier coating composition comprising polyvinyl alcohol as film former, soya lecithin as plasticizer and solubilizing agent and xanthan gum as stabilizer and suspension agent
  • the present invention relates to a pharmaceutical formulation having increased in-vitro dissolution, and reduced and controlled degradation under moisture and heat conditions comprising alpha ketoanalogue of amino acids and additional amino acids as active ingredients, and disintegrant, filler and binder, and coated with moisture barrier coating composition, wherein disintegrant is croscarmellose sodium, filler is microcrystalline cellulose and binder is polyvinyl pyrrolidone, and moisture barrier coating composition comprises film former, plasticizer and solubilizing agent, and stabilizer and suspension agent, wherein film former is polyvinyl alcohol, plasticizer and solubilizing agent is soya lecithin, and stabilizer and suspension agent is xanthan gum.
  • the present invention also relates to a pharmaceutical formulation having increased in-vitro dissolution, arid reduced and controlled degradation under moisture and heat conditions comprising alpha ketoanalogue of amino acids and additional amino acids as active ingredients, and disintegrant, filler and binder, wherein disintegrant is croscarmellose sodium, filler is microcrystalline cellulose and binder is polyvinyl pyrrolidone.
  • formulations of present invention have been found to have improved in-vitro dissolution, and reduced and controlled degradation of the drugs (the active ingredients) from the moisture and heat in the tested pack during their storage.
  • the inventors have also found that the formulations of present invention do not demonstrate surface spotted degradation and discoloration.
  • formulations of present invention are prepared by a dry granulation process while controlling the moisture absorption at every step of the process, it surprisingly and unexpectedly results in reduction of surface sensitivity of the tablet dosage form.
  • the present invention also relates to a process for preparation of pharmaceutical formulation for oral administration having increased in-vitro dissolution, and reduced and controlled degradation under moisture and heat conditions comprising steps of mixing alpha ketoanalogue of amino acids and additional amino acids homogeneously with disintegrant, filler and binder followed by dry granulation of the resulted blend, and optionally step of lubrication followed by compressing the core to tablet form and then coating with moisture barrier coating composition comprising film former, plasticizer and solubilizing agent, and stabilizer and suspension agent, wherein disintegrant is croscarmellose sodium, filler is microcrystalline cellulose and binder is polyvinyl pyrrolidone, and film former is polyvinyl alcohol, plasticizer and solubilizing agent is soya lecithin, and stabilizer and suspension agent is xanthan gum.
  • formulations of present invention having substantially increased in-vitro dissolution, and substantially reduced and controlled degradation under the moisture * and heat conditions even during its storage in the tablet dosage form are expected to have enhanced in-vivo bioavailability, of its active ingredients.
  • the scope of the present invention also includes a pharmaceutical formulation having increased in-vitro dissolution, and reduced and controlled degradation under moisture and heat conditions, and having enhanced in-vivo bioavailability of its active ingredients comprising alpha ketoanalogue of amino acids and additional amino acids as active ingredients, and croscarmellose sodium as disintegrant, microcrystalline cellulose as filler and polyvinyl pyrrolidohe as binder.
  • the scope of the present invention also includes a pharmaceutical formulation having increased in-vitro dissolution, and reduced and controlled degradation under moisture and heat conditions, and having enhanced in-vivo bioavailability of its active ingredients comprising alpha ketoanalogue of amino acids and additional amino acids as active ingredients, and croscarmellose sodium as disintegrant, microcrystalline cellulose as filler and polyvinyl pyrrolidone as binder, and coated with moisture barrier coating composition comprising polyvinyl alcohol as film former, soya lecithin as plasticizer and solubilizing agent and xanthan gum as stabilizer and suspension agent.
  • a pharmaceutical formulation having increased in-vitro dissolution, and reduced and controlled degradation under moisture and heat conditions, and having enhanced in-vivo bioavailability of its active ingredients comprising alpha ketoanalogue of amino acids and additional amino acids as active ingredients, and croscarmellose sodium as disintegrant, microcrystalline cellulose as filler and polyvinyl pyrrolidone as binder, and coated with moisture barrier coating composition comprising
  • the alpha ketoanalogue of amino acids are selected from a group comprising calcium -3- methyl-2-oxo-valerate (alpha-ketoanalogue to isoleucine, calcium salt), calcium 4-methyl-2-oxo-valerate (alpha-ketoanalogue to leucine, calcium salt), calcium-2-oxo-3-phenylpropionate (alpha-ketoanalogue to phenylalanine, calcium salt), calcium -3- methyl-2-oxo butyrate (alpha-ketoanalogue to valine, calcium salt), and calcium-DL-2-hydroxy- (methylthio)butyrate (alpha - hydroxyanalogue to methionine, calcium salt).
  • the additional amino acids are selected from a group comprising L-lysine acetate, L-threonine, L-tryptophan, L-histidine, and L- tyrosine.
  • the filler is taken in an amount varying from about 12 to about 25% w/w of the uncoated formulation, preferably in- an amount varying from about 15 to about 20% w/w of the uncoated formulation. :j,
  • it further comprises crospovidone as additional disintegrant.
  • the disintegrants comprising croscarmellose sodium and crospovidone are taken in an amount varying from about 4 to about 12% w/w of the uncoated formulation, preferably in an amount varying from about 8 to about 10% w/w of the uncoated formulation.
  • the croscarmellose sodium is employed as disintegrant in an amount varying from about 2 to about 6% w/w of the uncoated formulation, preferably in an amount varying from about 3 to about 5% w/w of the uncoated formulation.
  • the disintegrants croscarmellose sodium and crospovidone are taken in a weight ratio varying from about 1 : 1 to about 1: 1.50, preferably about 1:1.-25 in the uncoated formulation.
  • the present formulation further comprises colloidal silicon dioxide as co-disintegrant and glidant.
  • the disintegrants, additional disintegrant and co-disintegrant being respectively croscarmellose sodium, crospovidone and colloidal silicon dioxide are taken in an amount varying from about 8 to about 14% w/w of the uncoated formulation, preferably in an amount varying from about 9 to about 12% w/w of the uncoated formulation.
  • the co-disintegrant colloidal silicon dioxide is taken in an amount varying from about 0.5 to about 2% w/w of the uncoated formulation, preferably in an amount varying from about
  • the binder is a combination of polyvinyl pyrrolidone -90 and polyvinyl pyrrolidone K-30, which are taken in an amount varying from about 5 to about 9% w/w of the uncoated formulation, preferably in an amount varying from about 6 to about 8% w/w of the uncoated formulation.
  • the binder polyvinyl pyrrolidone K-90 is taken in higher amount than the binder polyvinyl pyrrolidone K-30.
  • the weight ratio of polyvinyl pyrrolidone K-90 to polyvinyl pyrrolidone K-30 preferably varies from about 1.10: 1 to about 1.20:1. In accordance with more preferred embodiment of the present invention, the weight ratio of polyvinyl pyrrolidone K-90 to polyvinyl pyrrolidone K-30 is about 1.16: 1. ,
  • the core of the formulation tablet is produced by dry granulation, which is then given m coating of present formulation, which has been found to have capability of preventing the core from degradation on contact with environmental moisture and heat, and from degradation in the tested pack during storage. Accordingly, the presently provided formulation has been found to have capabilities to protect the drugs— the active ingredients from the moisture and heat, and to prevent the drugs - the active . ingredients, from degradation during storage.
  • the coating is mpisture barrier coating composition comprising polyvinyl alcohol as film former, soya lecithin as plasticizer and solubilizing agent, and xanthan gum as stabilizer and suspension agent:
  • soya lecithin has been found to act as plasticizer and solubilizing agent
  • xanthan gum has been found to act as stabilizer and suspension agent.
  • moisture barrier coating composition comprising polyvinyl alcohol, soya lecithin and xanthan gum enhances the release of drug from the core tablet.
  • the coated formulation comprises about 5 to 7% of the moisture barrier coating composition.
  • moisture barrier coating composition comprises about 45.5% w /w of the polyvinyl alcohol as film former, about 2% w/w of the soya lecithin as plasticizer and solubilizing agent, about 0.5% w/w of the xanthan gum as stabilizer and suspension agent.
  • the moisture barrier coating composition as used in present invention additionally comprises excipients selected from the group comprising talcum, titanium dioxide, quinoline yellow, opacifire and colouring agent amounting to about 52%. v., ,,
  • coating compositions comprising hydroxy propyl methyl cellulose [HPMC], or hydroxyl ethyl cellulose [HEC], or sodium carboxy methyl cellulose [NaCMC], or ethyl cellulose [EC], or hydroxyl propyl cellulose [HPCJ as film former with other excipients including plasticizers, stabilizing agent and colourants did not show any reduction in surface discolouration and degradation on exposure to heat and moisture, and improvement in the in-vitro dissolution of the formulation.
  • HPMC hydroxy propyl methyl cellulose
  • HEC sodium carboxy methyl cellulose
  • HPCJ hydroxyl propyl cellulose
  • the inventors After lot of research work, the inventors have found that it is only the coating composition comprising polyvinyl alcohol as film former in combination with soya lecithin as plasticizer and solubilizing agent and xanthan gum as stabilizer and suspension agent, which surprisingly and unexpectedly, results in a formulation having substantially increased in-vitro dissolution, and substantially reduced and controlled degradation under the moisture and heat conditions even during the accelerated stability storage conditions as per ICH (International Conference on Harmonization) in its tablet dosage form.
  • the inventors have found that only the combination of polyvinyl alcohol, soya lecithin and xanthan gum results in the best suitable moisture barrier composition, which provides an effective moisture barrier, reduces moisture entrapment on the surface at the same time allows the drugs to permeate through the coating more effectively.
  • the moisture barrier coating composition used in present invention is one available from Colorcon as Opadry AMB readymix.
  • the core formulation further comprises lubricant.
  • the lubricating agent is selected from the group comprising magnesium stearate and sodium starch fumarate, preferably the lubricating agent is magnesium stearate.
  • the filler may be selected from the group comprising microcrystalline cellulose, lactose, dicalcium phosphate, and mannitol.
  • microcrystalline cellulose is used as filler in combination with other judiciously selected disintegrants and binders of present formulation, the present formulation demonstrates unexpectedly increased in-vitro dissolution, and unexpectedly reduced and controlled degradation.
  • microcrystalline cellulose is partially dep lymerized cellulose, white, odorless and tasteless powder composed of porous particles having about 90% particles of particle size varying from about 70 to 130 micr n, preferably of abopt 100 micron, and having moisture content less than 5%.
  • microcrystalline cellulose which is available as Avicel pH 102, surprisingly and unexpectedly, demonstrates better dissolution properties as compared to other grades of microcrystalline cellulose. Accordingly, the granular form of microcrystalline cellulose is most preferred in accordance with the present invention.
  • microcrystalline cellulose not only acts as filler, but also acts as a disintegrating agent due to its capillary action which gives bursting effect, thus lowering the disintegration time of the tablet on contact with aqueous medium.
  • the presently selected microcrystalline cellulose has been found to have unique compressibility and carrying capacity which exhibits excellent properties as an excipient for the present formulation. It was found to compact well under minimum compression pressures and to have high binding capability and capable of resulting in extremely hard and stable core tablets, and yet disintegrate rapidly.
  • the judiciously selected microcrystalline cellulose also demonstrates advantages of low friability, inherent lubricity, and highest diluting potential of all binders.
  • the judiciously selected microcrystalline cellulose acts as filler and as binder for the present formulation.
  • the selected microcrystalline cellulose has been found to be highly absorptive due to its capillary action of its surface porosity, which indicates that it may also be acting as a carrier for liquids and yet retain free flowing and compression properties of the formulation.
  • the disintegrant is combination of croscarmellose sodium and crospovidone.
  • the inventors have found that when disintegrant crospovidone is combined with croscarmellose sodium as in present invention, the in-vitro dissolution of active ingredients is substantially increased.
  • the croscarmellose sodium having loss of moisture on drying ⁇ 10.0% w/w, and pH of 5.0 to 7.0 in aqueous dispersion is preferred choice as it has been found effective in disintegrating large amounts of alpha ketoanalogure of amino acids and additional amino acids from the present tablet dosage form.
  • the crospovidone having loss of moisture on drying ⁇ 5.0% w/w and pH of 5.0 to 8.0 in 1 % w/v aqueous dispersion is preferred choice as it has been found effective in disintegrating large amounts of alpha ketoanalogure of aminp acids and additional amino acids from the present tablet dosage form.
  • the croscarmellose sodium is an internally crossed-linked sodium carboxymethyl cellulose, which due to its cross-linking has been found to have advantage of swelling in water, and as a result, the judiciously selected croscarmellose sodium has been found to provide superior drug disintegration and dissolution characteristics, and thereby improving the efficiency of the pharmaceutical formulation of present invention, which, accordingly, is expected to give better in-vivo bioavailability.
  • the binder may be selected from the group comprising carboxymethyl cellulose sodium, methyl cellulose, hydroxypropyl cellulose, and polyvinyl pyrrolidone.
  • the inventors have found that when polyvinyl pyrrolidone is used as binder, particularly when combination of polyvinyl pyrrolidone K-90 and polyvinyl pyrrolidone K-30 is used as binder in combination with other judiciously selected filler and disintegrants of present formulation, the present formulation demonstrates unexpectedly increased in-vitro dissolution, and unexpectedly reduced and controlled degradation.
  • the combination of polyvinyl pyrrolidone K-90 and polyvinyl pyrrolidone K-30 as binder has been found to enhance dissolution of the present formulation when used in combination with filler and disintegrant of the present invention.
  • the polyvinyl pyrrolidone-K-90 is one having molecular weight of about 10,00,000 and polyvinyl pyrrolidone-K-30 is one having molecular weight of about 50,000.
  • the combination of these polyvinyl pyrrolidones has been found to act as binder and as well as dissolution enhancer in present formulation to enhance its in-vitro dissolution.
  • the polyvinyl pyrrolidones are white hygroscopic powder with characteristic odor in contrast with most polymers which are readily soluble both in water as well as in a large number of organic solvents selected from the group comprising alcohol, amine, acid, amide, lactam. It has been found that due to increased solubility of polyvinyl pyrrolidones in aqueous medium, these serve as a dual phenomenon of binder as well as a dissolution .enhancer in present formulation.
  • the colloidal silicon dioxide used as co-disintegrant and glidant is the one having large specific surface area which has been found to have advantage of desirable flow characteristics which results in improvement of the flow properties of the present formulation thereby resulting in the formulation having advantage of absorbing moisture in the aqueous media to cause of swelling of the present formulation.
  • present pharmaceutical formulation comprising alpha ketoanalogue of amino acids and additional amino acids as active ingredients is non- ethanolic formulation.
  • present formulation when comprising above- described ingredients in above-described ratio, or relative amounts give more strength to the formulation in coated tablet dosage form resulting in the reduced friability.
  • the present pharmaceutical formulation comprising alpha ketoanalogue of amino acids and additional amino acids as active ingredients, and croscarmellose sodium and crospovidone as disintegrants, microcrystallihe cellulose as filler and polyvinyl pyrrolidone K-90 and polyvinyl pyrrolidone K-30 as binders, and coated with moisture barrier coating composition comprising polyvinyl alcohol as film former, soya lecithin as plasticizer and solubilizing agent and xanthan gum as stabilizer and suspension agent, demonstrates substantially increased in-vitro dissolution, and is substantially stable under moisture and heat conditions during its storage in the tablet dosage form, and demonstrates disintegration of the formulation in minimum possible duration, preferably in less than 30 minutes, which, in view of its substantially increased in-vitro dissolution, and substantially reduced and controlled degradation are indicative
  • formulations of present invention having substantially increased in-vitro dissolution, and substantially reduced and controlled degradation under the moisture and heat conditions even during its storage in the tablet dosage form are not only expected to have enhanced in-vivo bioavailability of its active ingredients, but are also expected to have improved patient compliance.
  • coated formulation may be used for treatment of chronic kidney disease, acute kidney disease, acute or chronic renal failure.
  • Expt. 1, Expt. 2, Expt. 3, Expt. 4 are for comparative purpose and Expt. 5 is in accordance with most preferred embodiment of the present invention, which is included with the scope of present invention.
  • the in-vitro dissolution, and degradation under the moisture and heat conditions were studied of all five formulations. It has been found that only the formulation , Qf Expt. 5 demonstrated substantially increased in-vitro dissolution, and substantially reduced and controlled degradation under the moisture and heat conditions.
  • the formulation of Expt. 5 was also subjected to stability storage test under accelerated stability storage conditions as per ICH (International Conference on Harmonization) in its tablet dosage form and surprisingly and unexpectedly found to be substantially stable.
  • coated tablets formed from formulation of Expt. 5 overcome problems of sensitivity of alpha ketoanalogue of amino acids and additional amino acids to heat and moisture even during storage, and demonstrate substantially increased in-vitro dissolution.
  • the inventors also confirm that during the in-vitro studies the active ingredients of the formulation of Expt. 5 get disintegrated from the formulation in less than 30 minutes on contact with aqueous medium.
  • the inventors also confirm that coated tablets coated with Instamoistshield or with Opadry film coating did not demonstrate increased in-vitro dissolution, and controlled degradation under the moisture and heat conditions *

Abstract

L'invention concerne une nouvelle formulation pharmaceutique d'alpha cétoanalogue d'acides aminés et d'acides aminés supplémentaires pour un traitement d'une maladie rénale chronique et son procédé de préparation. La présente invention concerne une formulation pharmaceutique ayant une dissolution in vitro accrue, et une dégradation réduite et contrôlée dans des conditions d'humidité et de chaleur, comprenant un alpha cétoanalogue d'acides aminés et des acides aminés supplémentaires en tant qu'ingrédients actifs, et un désintégrant, une charge et un liant, et enrobée par une composition d'enrobage barrière à l'humidité, le désintégrant étant de la croscarmellose sodique, la charge étant de la cellulose microcristalline et le liant étant de la polyvinyl pyrrolidone, et la composition d'enrobage barrière à l'humidité comprenant un agent filmogène, un plastifiant et agent solubilisant, et un stabilisant et agent de mise en suspension, l'agent filmogène étant l'alcool polyvinylique, le plastifiant et agent solubilisant étant de la lécithine de soja, et le stabilisant et agent de mise en suspension étant de la gomme xanthane. Dans un mode de réalisation, la présente invention concerne également un procédé de préparation de ladite formulation pharmaceutique.
PCT/IN2011/000647 2011-04-06 2011-09-21 Nouvelle formulation pharmaceutique d'alpha cétoanalogue d'acides aminés et d'acides aminés supplémentaires pour un traitement d'une maladie rénale chronique et son procédé de préparation WO2012137216A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1154MU2011 2011-04-06
IN1154/MUM/2011 2011-04-06

Publications (1)

Publication Number Publication Date
WO2012137216A1 true WO2012137216A1 (fr) 2012-10-11

Family

ID=45464041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000647 WO2012137216A1 (fr) 2011-04-06 2011-09-21 Nouvelle formulation pharmaceutique d'alpha cétoanalogue d'acides aminés et d'acides aminés supplémentaires pour un traitement d'une maladie rénale chronique et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2012137216A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908214A (en) * 1987-07-23 1990-03-13 Synthelabo Pharmaceutical tablet for the treatment of uraemia
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908214A (en) * 1987-07-23 1990-03-13 Synthelabo Pharmaceutical tablet for the treatment of uraemia
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate

Similar Documents

Publication Publication Date Title
TWI409064B (zh) Pharmaceutical composition
EP1928431B1 (fr) Composition pharmaceutique a liberation lente contenant carvedilol
KR100322340B1 (ko) 경구 콜레스테롤 저하제
US20060088594A1 (en) Highly compressible controlled delivery compositions of metformin
JPH0753365A (ja) γ−ヒドロキシ酪酸塩による制御放出能をもつ薬化学組成物
JP2013522373A (ja) 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
WO2006082523A2 (fr) Compositions pharmaceutiques de metformine
BRPI0709847B1 (pt) Composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
AU2008309385B2 (en) Zibotentan composition containing mannitol and/or microcrystalline cellulose
AU2014279743B2 (en) Modified release formulation
WO2008129517A2 (fr) Composition pharmaceutique à libération prolongée stabilisée de rabéprazole
EP1919459A1 (fr) Préparation pharmaceutique solide comprenant de la 1-(4-chloroanilino)-4-(4-pyridylméthyl)phtalazine et un modificateur de ph
CN107693515B (zh) 含碱化剂和艾曲泊帕的药物组合物及其用途
JP5120652B2 (ja) 固形医薬製剤
US8685448B2 (en) Pharmaceutical solid dosage form
WO1993000915A1 (fr) Comprimes a haute teneur en chlorhydrate de colestipol
SETHI et al. Formulation and in vitro evaluation of gastroretentive floating drug delivery system of ritonavir
JP5124286B2 (ja) 徐放性製剤およびその製造方法
WO2016101024A1 (fr) Procédé de traitement
JP2017523149A (ja) エドキサバンの医薬組成物
EP2386302A1 (fr) Forme pharmaceutique à libération prolongée de trimetazidine et ses procédés de préparation
WO2009027786A2 (fr) Formes posologiques matricielles de varénicline
JP2008094845A (ja) 医薬錠剤
TWI488658B (zh) 溶出性之改善方法
WO2012137216A1 (fr) Nouvelle formulation pharmaceutique d'alpha cétoanalogue d'acides aminés et d'acides aminés supplémentaires pour un traitement d'une maladie rénale chronique et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11805626

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11805626

Country of ref document: EP

Kind code of ref document: A1